FATE Q2 2024 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+625.8% YoY

Gross Profit

$2M30.3% margin

Operating Income

-$45M-665.7% margin

Net Income

-$38M-567.4% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+251.8%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$529M

Total Liabilities

$132M

Stockholders' Equity

$397M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$933,000	+625.8%
Gross Profit	$2M	-$40M	+105.1%
Operating Income	-$45M	-$63M	+27.9%
Net Income	-$38M	-$53M	+27.2%